Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch–Schönlein purpura, ankylosing spondylitis, and Raynaud’s phenomenon

References

• FauciASHaynesBFKatzPWolffSMWegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 yearsAnn Intern Med198398176856336643
   PubMed Web of Science ®Google Scholar
• FauciASWolffSMWegener’s granulomatosis: studies in eighteen patients and a review of the literatureMedicine (Baltimore)19735265355614748591
   PubMed Web of Science ®Google Scholar
• HoffmanGSKerrGSLeavittRYWegener granulomatosis: an analysis of 158 patientsAnn Intern Med199211664884981739240
   PubMed Web of Science ®Google Scholar
• WaltersGWillisNSCraigJCInterventions for renal vasculitis in adultsCochrane Database Syst Rev20159CD00323226400765
   PubMed Web of Science ®Google Scholar
• WestmanKWBygrenPGOlssonHRanstamJWieslanderJRelapse rate, renal survival, and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvementJ Am Soc Nephrol1998958428529596082
   PubMed Web of Science ®Google Scholar
• TaylorRPLindorferMADrug insight: the mechanism of action of rituximab in autoimmune disease – the immune complex decoy hypothesisNat Clin Pract Rheumatol200732869517299446
   PubMedGoogle Scholar
• ChatzidionysiouKLieENasonovEEffectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaborationArthritis Res Ther2016185026883119
   PubMed Web of Science ®Google Scholar
• RandallKLRituximab in autoimmune diseasesAust Prescr201639413113427756976
   PubMedGoogle Scholar
• SnellerMCHuZLangfordCAA randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitisArthritis Rheum201264383584222147444
   PubMed Web of Science ®Google Scholar
• SpecksUMerkelPASeoPEfficacy of remission-induction regimens for ANCA-associated vasculitisN Engl J Med2013369541742723902481
   PubMed Web of Science ®Google Scholar
• StoneJHMerkelPASpieraRRituximab versus cyclophosphamide for ANCA-associated vasculitisN Engl J Med2010363322123220647199
   PubMed Web of Science ®Google Scholar
• LetaiefHLukasCBarnetcheTGaujoux-VialaCCombeBMorelJEfficacy and safety of biological DMARDs modulating B cells in primary Sjögren’s syndrome: systematic review and meta-analysisJoint Bone Spine Epub2017630
   Web of Science ®Google Scholar
• InnamiKMukaiTKodamaSMoritaYSuccessful treatment using rituximab in a patient with refractory polymyositis complicated by scleroderma renal crisisBMJ Case Rep20172017221205
   Google Scholar
• MelsensKVandecasteeleEDeschepperETwo years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosisActa Clin Belg Epub2017911
   Google Scholar
• OddisCVReedAMAggarwalRRituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trialArthritis Rheum201365231432423124935
   PubMed Web of Science ®Google Scholar
• DavatchiFShamsHRezaipoorMRituximab in intractable ocular lesions of Behçet’s disease; randomized single-blind control study (pilot study)Int J Rheum Dis201013324625220704622
   PubMed Web of Science ®Google Scholar
• SadreddiniSNoshadHMolaeefardMNoshadRTreatment of retinal vasculitis in Behçet’s disease with rituximabMod Rheumatol200818330630818438602
   PubMed Web of Science ®Google Scholar
• ZhaoBHOswaldAEImproved clinical control of a challenging case of Behçet’s disease with rituximab therapyClin Rheumatol201433114915024305944
   PubMed Web of Science ®Google Scholar
• JonesRBFurutaSTervaertJWRituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trialAnn Rheum Dis20157461178118225739829
   PubMed Web of Science ®Google Scholar
• HendersonSRCopleySJPuseyCDIndPWSalamaADProlonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA)Medicine (Baltimore)20149327e22925501085
   PubMed Web of Science ®Google Scholar
• Recillas-GispertCSerna-OjedaJCFlores-SuarezLFRituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener’s)Graefes Arch Clin Exp Ophthalmol2015253122279228426507398
   PubMed Web of Science ®Google Scholar
• WangCHFinkelRSBertiniESConsensus statement for standard of care in spinal muscular atrophyJ Child Neurol20072281027104917761659
   PubMed Web of Science ®Google Scholar
• JonesRBTervaertJWHauserTRituximab versus cyclophosphamide in ANCA-associated renal vasculitisN Engl J Med2010363321122020647198
   PubMed Web of Science ®Google Scholar
• SpecksUMerkelPAHoffmanGSDesign of the Rituximab in ANCA-Associated Vasculitis (RAVE) TrialOpen Arthritis J20114118
   Google Scholar
• GeethaDSpecksUStoneJHRituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvementJ Am Soc Nephrol201526497698525381429
   PubMed Web of Science ®Google Scholar
• NagafuchiHAtsumiTHattaKLong-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitisMod Rheumatol201525460360825496405
   PubMed Web of Science ®Google Scholar
• WendtMGunnarssonIBrattJBruchfeldARituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patientsScand J Rheumatol201241211611922118245
   PubMed Web of Science ®Google Scholar
• de MenthonMCohenPPagnouxCInfliximab or rituximab for refractory Wegener’s granulomatosis – long-term follow up: a prospective randomised multicentre study on 17 patientsClin Exp Rheumatol2011291 Suppl 64S63S71
   Web of Science ®Google Scholar
• LovricSErdbrueggerUKümpersPRituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patientsNephrol Dial Transplant200924117918518685144
   PubMed Web of Science ®Google Scholar
• Cartin-CebaRGolbinJMKeoghKARituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single centerArthritis Rheum201264113770377822730028
   PubMed Web of Science ®Google Scholar
• RheeEPLaliberteKANilesJLRituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitisClin J Am Soc Nephrol2010581394140020498238
   PubMed Web of Science ®Google Scholar
• Roubaud-BaudronCPagnouxCMeaux-RuaultNRituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitisJ Rheumatol201239112513022089465
   PubMed Web of Science ®Google Scholar
• GuillevinLPagnouxCKarrasARituximab versus azathioprine for maintenance in ANCA-associated vasculitisN Engl J Med2014371191771178025372085
   PubMed Web of Science ®Google Scholar
• SmithRMJonesRBGuerryMJRituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitisArthritis Rheum201264113760376922729997
   PubMed Web of Science ®Google Scholar
• AwadNHafizSAlbeityAAlmoallimHA case of rituximab use as an induction and maintenance of remission in ANCA-associated vasculitisCase Rep Rheumatol20162016727586027006851
   PubMedGoogle Scholar
• MoogPProbstMKuechleCHauserCHeemannUThuermelKSingle-dose rituximab for remission induction and maintenance therapy in ANCA-associated vasculitis: a retrospective analysis of 17 patientsScand J Rheumatol201443651952325179776
   PubMed Web of Science ®Google Scholar
• CalichALPuechalXPugnetGRituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener’s): results of a single-center cohort study on 66 patientsJ Autoimmun20145013514124703438
   PubMed Web of Science ®Google Scholar
• CharlesPNéelATieuliéNRituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patientsRheumatology (Oxford)201453353253924282319
   PubMed Web of Science ®Google Scholar
• PendergraftWFCortazarFBWengerJLong-term maintenance therapy using rituximab-induced continuous B-Cell depletion in patients with ANCA vasculitisClin J Am Soc Nephrol20149473674424626432
   PubMed Web of Science ®Google Scholar
• BesadaEKoldingsnesWNossentJCLong-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centreRheumatology (Oxford)201352112041204723934313
   PubMed Web of Science ®Google Scholar
• Brodowska-KaniaDRymarzASaracynMGeislerPNiemczykSZastosowanie rituksimabu w indukcji remisji ciężkiej, opornej na leczenie postaci zapalenia naczyń z obecnością przeciwciał c-ANCA – opis przypadku [Use of rituximab in the induction of remission of severe, resistant and recurrent form of polyangiitis associated with c-ANCA antibodies: case report]Pol Merkur Lekarski201538226216218 Polish25938389
   PubMedGoogle Scholar
• UmezawaNKohsakaHNankiTSuccessful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIgMod Rheumatol201424468568724517553
   PubMed Web of Science ®Google Scholar
• ThielJHasslerFSalzerUVollREVenhoffNRituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)Arthritis Res Ther2013155R13324286362
   PubMed Web of Science ®Google Scholar
• MohammadAJHotAArndtFRituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)Ann Rheum Dis201675239640125467294
   PubMed Web of Science ®Google Scholar
• PraisDAmirJNussinovitchMRecurrent Henoch-Schönlein purpura in childrenJ Clin Rheumatol2007131252817278945
   PubMed Web of Science ®Google Scholar
• CoppoRAndrulliSAmoreAPredictors of outcome in Henoch-Schönlein nephritis in children and adultsAm J Kidney Dis2006476993100316731294
   PubMed Web of Science ®Google Scholar
• DonnithorneKJAtkinsonTPHinzeCHRituximab therapy for severe refractory chronic Henoch-Schönlein purpuraJ Pediatr2009155113613919559299
   PubMed Web of Science ®Google Scholar
• PilleboutERochaFFardetLRybojadMVerineJGlotzDSuccessful outcome using rituximab as the only immunomodulation in Henoch-Schönlein purpura: case reportNephrol Dial Transplant20112662044204621436378
   PubMed Web of Science ®Google Scholar
• SaadounDRigonMRSeneDRituximab plus PEG-interferon-α/ribavirin compared with PEG-interferon-α/ribavirin in hepatitis C-related mixed cryoglobulinemiaBlood2010116332633420439619
   PubMed Web of Science ®Google Scholar
• SaadounDResche-RigonMSeneDPerardLKarrasACacoubPRituximab combined with PEG-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitisAnn Rheum Dis200867101431143618178690
   PubMed Web of Science ®Google Scholar
• De VitaSQuartuccioLIsolaMA randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitisArthritis Rheum201264384385322147661
   PubMed Web of Science ®Google Scholar
• TerrierBSaadounDSèneDEfficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup [sic] study of thirty-two patientsArthritis Rheum20096082531254019644879
   PubMed Web of Science ®Google Scholar
• DammaccoFTucciFALaulettaGPEGylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term studyBlood2010116334335320308602
   PubMed Web of Science ®Google Scholar
• VisentiniMLudovisiSPetrarcaAA phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infectionAutoimmun Rev2011101171471921570494
   PubMed Web of Science ®Google Scholar
• VisentiniMTinelliCColantuonoSEfficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic reviewAutoimmun Rev2015141088989626031898
   PubMed Web of Science ®Google Scholar
• PetrarcaARigacciLMontiMImprovement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximabDig Liver Dis200739Suppl 1S129S13317936214
   PubMedGoogle Scholar
• LamprechtPLerin-LozanoCMerzHRituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitisAnn Rheum Dis200362121230123314644867
   PubMed Web of Science ®Google Scholar
• NocturneGDougadosMConstantinARituximab in the spondyloarthropathies: data of eight patients followed up in the French autoimmunity and rituximab (AIR) registryAnn Rheum Dis201069247147220107035
   PubMed Web of Science ®Google Scholar
• SongIHHeldmannFRudwaleitMDifferent response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trialArthritis Rheum20106251290129720461780
   PubMed Web of Science ®Google Scholar
• KobakSKaraarslanAOkselFThe efficacy and safety of rituximab in a patient with rheumatoid spondylitisCase Rep Rheumatol2013201379252624324911
   PubMedGoogle Scholar
• Rodríguez-EscaleraCFernández-NebroAThe use of rituximab to treat a patient with ankylosing spondylitis and hepatitis BRheumatology (Oxford)200847111732173318786966
   PubMed Web of Science ®Google Scholar
• HuangYChengFZhangXTangJMarked reduction of sacroiliac joint inflammation on magnetic resonance imaging in a patient with ankylosing spondylitis after rituximab treatmentJ Rheumatol20113892083208421885528
   PubMed Web of Science ®Google Scholar
• OmairMAAlnaqbiKALeePRituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literatureClin Rheumatol20123181259126122644089
   PubMed Web of Science ®Google Scholar
• AldhaheriFAlmteriTDwidNMajdaliAJanoudiNAlmoallimHRituximab can induce remission in a patient with ankylosing spondylitis who failed anti-TNF-α agentAm J Case Rep20171814314728179619
   PubMed Web of Science ®Google Scholar
• HaroonMO’GradaighDFoley-NolanDA case of Raynaud’s phenomenon in mixed connective tissue disease responding to rituximab therapyRheumatology (Oxford)200746471871917289791
   PubMed Web of Science ®Google Scholar
• DunkleyLGreenMGoughAComment on: a case of Raynaud’s phenomenon in mixed connective tissue disease responding to rituximab therapy responseRheumatology (Oxford)200746101628162917766999
   PubMed Web of Science ®Google Scholar
• RechJKallertSHueberAJRequadtCKaldenJRSchulze-KoopsHCombination of immunoadsorption and CD20 antibody therapy in a patient with mixed connective tissue diseaseRheumatology (Oxford)200645449049116461439
   PubMed Web of Science ®Google Scholar
• ShabrawishiMAlbeityAAlmoallimHSevere primary Raynaud’s disease treated with rituximabCase Rep Rheumatol20162016205380427651971
   PubMedGoogle Scholar
• SpecksUFervenzaFCMcDonaldTJHoganMCResponse of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapyArthritis Rheum200144122836284011762944
   PubMed Web of Science ®Google Scholar
• DalakasMCB cells as therapeutic targets in autoimmune neurological disordersNat Clin Pract Neurol200841055756718813230
   PubMedGoogle Scholar
• RiveraAChenCCRonNDoughertyJPRonYRole of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrationsInt Immunol200113121583159311717199
   PubMed Web of Science ®Google Scholar
• BraunJBollowMNeureLUse of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitisArthritis Rheum19953844995057718003
   PubMed Web of Science ®Google Scholar
• AppelHKuhneMSpiekermannSImmunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitisArthritis Rheum20065492845285116947385
   PubMed Web of Science ®Google Scholar
• AppelHLoddenkemperCGrozdanovicZCorrelation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitisArthritis Res Ther200685R14316925803
   PubMed Web of Science ®Google Scholar
• DornerTCrossroads of B cell activation in autoimmunity: rationale of targeting B cellsJ Rheumatol Suppl20067731116652439
   PubMedGoogle Scholar
• MintzGEnriquezRDMercadoURoblesEJJimenezFJGutierrezGIntravenous methylprednisolone pulse therapy in severe ankylosing spondylitisArthritis Rheum19812457347367236329
   PubMed Web of Science ®Google Scholar
• RichterMBWooPPanayiGSTrullAUngerAShepherdPThe effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitisClin Exp Immunol198353151596223736
   PubMed Web of Science ®Google Scholar
• CohenSBEmeryPGreenwaldMWRituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeksArthritis Rheum20065492793280616947627
   PubMed Web of Science ®Google Scholar
• PrevooMLvan ‘t HofMAKuperHHvan LeeuwenMAvan de PutteLBvan RielPLModified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis Rheum199538144487818570
   PubMed Web of Science ®Google Scholar
• AlbericiFSmithRCassiaMClinical predictors of response to rituximab in ANCA-associated vasculitis: a European cohortPoster presented at: 53rd European Renal Association–European Dialysis and Transplant Association CongressMay 21–24, 2016Vienna, Austria
   Google Scholar
• KosmidisMLDalakasMCPractical considerations on the use of rituximab in autoimmune neurological disordersTher Adv Neurol Disord2010329310521179602
   PubMedGoogle Scholar